Sponsors

Oncology assays in development

BD Diagnostics and Lab21 are to collaborate to develop oncology assays for the BD MAX fully automated bench-top molecular system. Under the terms of the collaboration, Lab21 will develop polymerase chain reaction-based assays on the BD MAX platform for a series of oncology markers, while BD will be responsible for manufacturing and commercialising the tests worldwide.

The first two assays will be designed to detect mutations in the KRAS and BRAF genes. These initial assays were selected because of their current importance in optimising the management of cancer patients. The agreement also includes the development of new nucleic acid extraction procedures from formalin-fixed paraffin-embedded tissue.
www.bd.com
www.lab21.com

Latest Issues

RSM / Path Soc 2026 Winter Meeting

The Royal Society of Medicine, 1 Wimpole St, London, W1G 0AE
20 - 21 January, 2026

BIVDA Regulatory Affairs Seminar

Grand Hotel, Birmingham
10 - 11 February, 2026

BDIAP Molecular Pathology Study Day

10 Union Street, London, SE1 1SZ
2 March, 2026

USCAP 115th Annual Meeting

Henry B. González Convention Center, San Antonio, Texas, USA
21 - 26 March, 2026

Microbiology Society Annual Conference 2026

ICC Belfast, Northern Ireland
13 - 16 April, 2026